Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02YEG
|
|||
| Former ID |
DIB006170
|
|||
| Drug Name |
VBY-376
|
|||
| Synonyms |
Protease inhibitor (hepatitis C virus infection), Virobay
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Virobay Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus NS3 helicase (HCV NS3) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00557583) Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults. U.S. National Institutes of Health. | |||
| REF 2 | Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.